Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Common Shares, $0.01 par value
-
Shares outstanding
-
28.9M
-
Number of holders
-
75
-
Total 13F shares, excl. options
-
9.16M
-
Shares change
-
+286K
-
Total reported value, excl. options
-
$117M
-
Value change
-
+$3.72M
-
Number of buys
-
44
-
Number of sells
-
-24
-
Price
-
$12.81
Significant Holders of abrdn Life Sciences Investors - Common Shares, $0.01 par value (HQL) as of Q2 2025
87 filings reported holding HQL - abrdn Life Sciences Investors - Common Shares, $0.01 par value as of Q2 2025.
abrdn Life Sciences Investors - Common Shares, $0.01 par value (HQL) has 75 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 9.16M shares
of 28.9M outstanding shares and own 31.74% of the company stock.
Largest 10 shareholders include Saba Capital Management, L.P. (3.02M shares), Penserra Capital Management LLC (770K shares), MORGAN STANLEY (766K shares), Royal Bank of Canada (451K shares), Karpus Management, Inc. (431K shares), NEEDHAM INVESTMENT MANAGEMENT LLC (392K shares), RAYMOND JAMES FINANCIAL INC (376K shares), LPL Financial LLC (344K shares), FLAGSHIP HARBOR ADVISORS, LLC (342K shares), and Allspring Global Investments Holdings, LLC (235K shares).
This table shows the top 75 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.